Crossmark

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China

Published Online: 2021-08-21

Published Print: 2021-10

Authors

Gong, Jinhong

Wan, Qian

Shang, Jingjing

Qian, Xiaodan

Su, Dan

Sun, Zhiqiang https://orcid.org/0000-0003-1977-5263
Liu, Guangjun
Funding

Funding for this research was provided by:

Medical Pharmacy Fund of Jiangsu Pharmaceutical Association (Q202031; A202022)

Changzhou Sci & Tech Program (CJ20209013, CE20195048)
License Information

Text and Data Mining valid from 2021-08-21

Version of Record valid from 2021-08-21
More Information

Article History

Received: 24 May 2021

Accepted: 4 August 2021

First Online: 21 August 2021

Document is current